PUBLISHER: Future Markets, Inc. | PRODUCT CODE: 2110462
PUBLISHER: Future Markets, Inc. | PRODUCT CODE: 2110462
Synthetic biology applies engineering principles to living systems, designing and constructing biological parts, devices and organisms that do not occur in nature, or redesigning existing ones for defined purposes. It differs from conventional genetic engineering in both ambition and method. Where genetic engineering introduces limited, targeted modifications to an existing organism, synthetic biology treats biology as a programmable platform, engineered through iterative design-build-test-learn cycles that draw on molecular biology, engineering, computer science and automation. The outputs are correspondingly different: not merely enhanced organism traits, but novel organisms, metabolic pathways and biomolecules.
The field spans a broad technology base. DNA synthesis and assembly, genome engineering, metabolic engineering, protein and enzyme engineering, synthetic genomics and computational design form the core toolset, supported by automated biofoundries, biosensors, robotics and expanding capability in xenobiology and cell-free systems. These tools are deployed across an unusually wide range of end markets - pharmaceuticals and healthcare, bio-based chemicals, bioplastics and biopolymers, biofuels, agriculture, food and nutraceutical ingredients, textiles, packaging, cosmetics, surfactants, construction materials, biocatalysis and bioremediation.
Three structural shifts define the current period. The first is convergence. Synthetic biology, industrial enzymes and white biotechnology were historically analysed as separate sectors; they now share the same toolsets, the same customers and increasingly the same balance sheets, making separate segmentation artificial and treating them as one industrial biomanufacturing market more accurate.
The second is the elevation of policy from background condition to primary determinant. Regulatory frameworks and industrial strategy in the European Union, United States and Asia now materially shape where production capacity is built and which products reach market first, with demand-side measures such as bio-based content requirements and public procurement preferences potentially more consequential than approval-pathway reform.
The third, and the most important commercially, is that scale-up remains the binding constraint. Laboratory and bench results reproduce reliably. The transition to commercial fermentation volumes exposes oxygen transfer limits, heat removal constraints, contamination risk, feedstock variability and downstream recovery losses that were invisible at small scale and that routinely destroy process economics. This gap explains the recurring pattern of well-funded platform companies failing between late-stage financing and commercial launch.
The consequence is a bifurcating market. Companies with production assets, contract manufacturing relationships or access to shared pilot infrastructure are converting technical capability into revenue. Those licensing technology alone remain exposed to the biotechnology funding cycle. Consolidation is expected to continue.
This report provides a comprehensive analysis of the global synthetic biology and biomanufacturing market across the 2027-2037 period, with historical context from 2019. It assesses the technical, commercial and regulatory factors shaping the sector, and segments the market by technology platform, product type, application sector and geography. Coverage extends across the applications in which synthetic biology is being commercialised: biofuels, bio-based chemicals, bioplastics and biopolymers, bioremediation, biocatalysis, food and nutraceutical ingredients, sustainable agriculture, textiles, packaging, healthcare and pharmaceuticals, cosmetics, surfactants and detergents, and construction materials.
Technology analysis covers biomanufacturing processes from batch and continuous fermentation through cell-free synthesis, biofilm-based production, microfluidic systems, photobioreactors, membrane bioreactors, plant and mammalian cell culture and bioprinting. It also examines metabolic engineering, gene and DNA synthesis, gene synthesis and assembly, genome engineering, protein and enzyme engineering, synthetic genomics, strain construction and optimisation, smart bioprocessing, chassis organisms, biomimetics, sustainable materials, robotics and automation, bioinformatics and computational tools, xenobiology and expanded genetic alphabets, biosensors and bioelectronics, feedstocks, and marine biotechnology.
The report includes a detailed technology roadmap to 2037, SWOT analysis, assessment of industry challenges and constraints, analysis of the scale-up and pilot infrastructure bottleneck that continues to determine which companies reach commercial production, the regulatory and policy landscape across the European Union, United States and Asia, the industrial biotechnology value chain, the convergence of synthetic biology with industrial enzymes and white biotechnology, and a review of investment activity across the sector.
The report contains 137 tables, 68 figures and profiles of 327 companies spanning the synthetic biology value chain, from DNA synthesis and biofoundry platforms through fermentation producers, materials companies and end-market brands. Companies profiled include Aanika Biosciences, Aemetis, AEP Polymers, Afyren, AgBiome, AgriSea NZ Seaweed, Agrivida, Ainnocence, AIO, AI Proteins, Algal Bio, Algenol, AlgiKnit, Algiecel, Alpha Biofuels, Allonnia, Allozymes, Alt.Leather, Alto Neuroscience, Amano Enzyme, AmphiStar, Amply Discovery, AMSilk, Amyris, Andes Ag, Ansa Biotechnologies, Antheia, Apeel Sciences, Aralez Bio, Arctic Biomaterials, Ardra Bio, Arkeon, Arsenale Bioyards, Arzeda, Asimov, Atantares, Autolus, AVA Biochem, Avantium, Azolla, Axcelon Biopolymers, Basecamp Research, BBCA Biochemical & GALACTIC Lactic Acid, Benefuel, BioBetter, Bioextrax, Bio Fab NZ, Biokemik, BIOLO, Biomason, Biomemory, Bioplastech, BioSmart Nano, Biotic Circular Technologies, Biosyntia, Biotecam, Bioweg, bit.bio, Bloom Biorenewables, BluCon Biotech, Blue BioFuels, Bluepha, Bon Vivant, Bolt Threads, Bosk Bioproducts, Bowil Biotech, Braskem, Brightseed, Bucha Bio, C1 Green Chemicals, C16 Biosciences, CABIO Biotech, California Cultured, Calysta, Cambrium, Camena Bioscience, Capra Biosciences, Carbios, Cargill, Calyxt, Cascade Biocatalysts, Cass Materials, Catalyxx, Cathy Biotech, Cauldron Ferm, Cemvita Factory, ChainCraft, Checkerspot, Chitose Bio Evolution, CinderBio, Circe, CJ Biomaterials, Clean Food Group, Codagenix, Codexis, Colossal Biosciences, Colipi, Colorifix, Conagen, Constructive Bio, Cysbio, Danimer Scientific, Debut Biotechnology, Deep Branch Biotechnology, Demetrix, Dispersa, DMC Biotechnologies, DNA Script, Domsjo Fabriker, DoriNano, DuPont, Earli, Ecovative Design, Eco Fuel Technology, Eden Brew, EggPlant, Eligo Bioscience, Elo Life Systems, Emerging Fuels Technology, Enduro Genetics, EnginZyme, Eni, EnPlusOne Biosciences, Enzymaster, Enzymit, Erebagen, Esphera SynBio, Euglena, Eversyn, Evozyne, FabricNano, Fermentalg, Forage Evolution and more......